17 November 2016
MaaT Pharma announces first positive DSMB safety review and continuation of its Phase 1b ODYSSEE study
MaaT Pharma ODYSSEE Study focuses in prevention of dysbiosis complications with autologous fecal microbiota transplantation in Acute Myeloid Leukemia patients undergoing...